A randomised, controlled trial of cognitive and psychomotor recovery from midazolam sedation following reversal with oral flumazenil

Nick Girdler, John Peter Lyne, R. Wallace, Nick Neave, Andrew Scholey, Keith Wesnes, C. Herman

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)

Abstract

Flumazenil is traditionally administered intravenously to reverse the adverse effects of over sedation with benzodiazepines. The aim of this study was to test postoperative cognitive and psychomotor recovery from midazolam conscious sedation, following reversal with orally administered flumazenil. It was hypothesised that when administered by the oral route, flumazenil may enhance recovery over a prolonged period, thus increasing safety. Eighteen patients requiring intravenous midazolam sedation for dental treatment completed a randomised, double-blind, crossover trial. Following treatment the patients' sedation was reversed using either flumazenil or saline (as placebo), administered orally, on alternate appointments. Assessment of mood and cognitive function were undertaken using ClinPhone.cdr®, a highly sensitive and specific computerised battery of cognitive tests administered by telephone prior to sedation and every hour for seven hours post reversal. Results indicate that within 20 min of administration, oral flumazenil is capable of partially reversing some cognitive and psychomotor impairments but the attentional and stimulus discrimination effects of midazolam sedation still remain.
Original languageEnglish
Pages (from-to)868-876
JournalAnaesthesia
Volume57
Issue number9
DOIs
Publication statusPublished - Sep 2002

Fingerprint

Dive into the research topics of 'A randomised, controlled trial of cognitive and psychomotor recovery from midazolam sedation following reversal with oral flumazenil'. Together they form a unique fingerprint.

Cite this